Location History:
- Osaka, JP (2002 - 2008)
- Takatsuki, JP (2007 - 2015)
Company Filing History:
Years Active: 2002-2015
Title: Kimiya Maeda: Innovator in CETP Activity Inhibition
Introduction
Kimiya Maeda is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit CETP activity. With a total of seven patents to his name, Maeda's work has the potential to impact the treatment of various lipid-related conditions.
Latest Patents
One of Maeda's latest patents focuses on CETP activity inhibitors. This invention provides a compound that selectively inhibits CETP activity, which can lead to an increase in HDL levels while decreasing LDL levels. The compound is also proposed for use in preventing or treating atherosclerosis and hyperlipidemia. Another significant patent involves dibenzylamine compounds, which exhibit selective and potent CETP inhibitory activity. These compounds can serve as therapeutic or prophylactic agents for hyperlipidemia and arteriosclerosis.
Career Highlights
Throughout his career, Kimiya Maeda has worked with prominent companies, including Japan Tobacco Inc. His experience in the pharmaceutical industry has allowed him to develop innovative solutions to complex health issues. His contributions to the field are recognized through his multiple patents and ongoing research.
Collaborations
Maeda has collaborated with notable colleagues such as Hisashi Shinkai and Hiroshi Okamoto. These partnerships have likely enhanced the scope and impact of his research efforts.
Conclusion
Kimiya Maeda is a distinguished inventor whose work in CETP activity inhibition has the potential to transform the treatment landscape for lipid-related diseases. His innovative patents and collaborations underscore his commitment to advancing pharmaceutical science.